Ocrelizumab extended‐interval dosing in multiple sclerosis during <scp>SARS‐CoV</scp>‐2 pandemic: a real‐world experienceSimone Guerrieri, Massimo Filippi, Chiara Bucca et al.|European Journal of Neurology|2023Cited by 29
Gray Matter Damage Predicts Disability Worsening, Cognitive Decline, and Mortality in Multiple Sclerosis after 26 Years (P5-19.002)Massimo Filippi, Maria Rocca, Marco Rovaris et al.|Neurology|2026Cited by 0
Gray Matter Damage and Long-Term Disability, Cognitive Outcome, and Survival in Patients With Multiple SclerosisPaolo Preziosa, Massimo Filippi, Alessandro Meani et al.|Neurology|2026Cited by 0